Identification and Development of an Efficient Route to SB-649915

Citations Over Time

Abstract

The discovery and development of an efficient manufacturing route to the SSRI-5-HT1A receptor antagonist 6-[(1-{2-[(2-methyl-5-quinolinyl)oxy]ethyl}-4-piperidinyl)methyl]-2H-1,4-benzoxazin-3(4H)-one (SB-649915) 1 is described. The existing route to 1 involved coupling quinoline 6 with piperidine 5 and was considered lengthy as a consequence of the nine synthetic steps required to prepare 5. Two new routes to the key piperidine intermediate 5 are identified which deliver this compound in five and two steps respectively, from readily available materials using novel lithiation and Friedel–Crafts methodology respectively. The latter of these two routes was successfully demonstrated at 5 L scale to deliver 700 g of 5. Development to the methanesulfonate 34, an alternative to quinoline 6, is also described as is the final alkylation of piperidine 5 with this methanesulfonate 34 to deliver SB-649915 1.

Related Papers

• → METABOLITES OF PIPERIDINE IN RAT URINE(1978)17 cited
• → An Efficient Synthesis of Aldohexose-Derived Piperidine Nitrones: Precursors of Piperidine Iminosugars(2013)4 cited
• Synthesis of Mercaptoalkoxy quinoline Compounds(2002)
• → Synthesis of benzo[g]quinoline derivatives(1970)
• → Carcinogenic Activity of Analogues of <italic>p</italic>-Dimethylaminoazobenzene. IV. Activity of the Quinoline Analogues<xref ref-type="fn" rid="FN1">2</xref>(1961)